Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Charles Mowbray"'
Autor:
Irfan Ullah, Fanny Escudie, Ivan Scandale, Zoela Gilani, Gabrielle Gendron-Lepage, Fleur Gaudette, Charles Mowbray, Laurent Fraisse, Renée Bazin, Andrés Finzi, Walther Mothes, Priti Kumar, Eric Chatelain, Pradeep D. Uchil
Publikováno v:
iScience, Vol 27, Iss 3, Pp 109049- (2024)
Summary: Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses w
Externí odkaz:
https://doaj.org/article/908e78da1f6147bc831d52e301a5e673
Autor:
Shingai Machingaidze, Carmen Pérez Casas, Sheila Mburu, Ruxandra Draghia-Akli, Charles Mowbray, James Rosen, Esteban Burrone, Mona Nemer, Victor Dzau
Publikováno v:
PLOS Global Public Health, Vol 4, Iss 8, p e0003654 (2024)
Externí odkaz:
https://doaj.org/article/09ef3fd05320444ca5e1eaf894b6d9b1
Autor:
Gathsaurie Neelika Malavige, Peter Sjö, Kavita Singh, Jean-Michel Piedagnel, Charles Mowbray, Sergio Estani, Steven Chee Loon Lim, Andre M Siqueira, Graham S Ogg, Laurent Fraisse, Isabela Ribeiro
Publikováno v:
PLOS Global Public Health, Vol 4, Iss 7, p e0003499 (2024)
[This corrects the article DOI: 10.1371/journal.pgph.0002598.].
Externí odkaz:
https://doaj.org/article/0f4f1b6d69de4af7acc89646f4c97828
Autor:
Gathsaurie Neelika Malavige, Peter Sjö, Kavita Singh, Jean-Michel Piedagnel, Charles Mowbray, Sergio Estani, Steven Chee Loon Lim, Andre M Siquierra, Graham S Ogg, Laurent Fraisse, Isabela Ribeiro
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 12, p e0002598 (2023)
Dengue is the most rapidly emerging mosquito-borne infection and, due to climate change and unplanned urbanization, it is predicted that the global burden of dengue will rise further as the infection spreads to new geographical locations. Dengue-ende
Externí odkaz:
https://doaj.org/article/4b479bf1d4a94a02a1f0c8ee17878792
Autor:
Taisuke Tawaraishi, Atsuko Ochida, Yuichiro Akao, Sachiko Itono, Masahiro Kamaura, Thamina Akther, Mitsuyuki Shimada, Stacie Canan, Sanjoy Chowdhury, Yafeng Cao, Kevin Condroski, Ola Engkvist, Amanda Francisco, Sunil Ghosh, Rina Kaki, John M. Kelly, Chiaki Kimura, Thierry Kogej, Kazuya Nagaoka, Akira Naito, Garry Pairaudeau, Constantin Radu, Ieuan Roberts, David Shum, Nao-aki Watanabe, Huanxu Xie, Shuji Yonezawa, Osamu Yoshida, Ryu Yoshida, Charles Mowbray, Benjamin Perry
Publikováno v:
Journal of Medicinal Chemistry. 66:1221-1238
Publikováno v:
The Handbook of Medicinal Chemistry ISBN: 9781788018982
Not every life-threatening or debilitating disease has a sufficient armoury of therapies available nor a pipeline of future products to combat the remaining unmet areas of medical need. This is particularly so in the areas of infectious diseases affe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d0f5a3a130926c43548332565a5940a
https://doi.org/10.1039/9781788018982-00873
https://doi.org/10.1039/9781788018982-00873
Autor:
Kirandeep Samby, Dominique Besson, Anirban Dutta, Buddhadev Patra, Angelique Doy, Paul Glossop, James Mills, Gavin Whitlock, Rob Hooft van Huijsduijnen, Alessandra Monaco, Graeme Bilbe, Charles Mowbray, Benjamin Perry, Anna Adam, Timothy N. C. Wells, Paul A. Willis
Publikováno v:
ACS Infectious Diseases. 8:713-720
The current Covid-19 pandemic has underlined the need for a more coordinated and forward-looking investment in the search for new medicines targeting emerging health care threats. Repositioning currently approved drugs is a popular approach to any ne
Publikováno v:
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 142(7)
The Neglected Tropical Disease (NTD) Drug Discovery Booster is a collaborative project in early small molecule drug discovery running since 2015 between Drugs for Neglected Diseases initiative (DNDi) and pharmaceutical partners across the globe, incl
Autor:
Gert-Jan, Wijnant, Simon L, Croft, Raul, de la Flor, Mo, Alavijeh, Vanessa, Yardley, Stéphanie, Braillard, Charles, Mowbray, Katrien, Van Bocxlaer
Publikováno v:
Antimicrobial Agents and Chemotherapy
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also shows potent in vitro and in vivo activity against cutaneous leishmaniasis (CL). To support further development of this compound into a patient-friend